Description
PT-141 10mg — melanocortin receptor agonist for sexual function research in Australia. University-verified ≥99% purity. Same-day Sydney dispatch.
PT-141 (Bremelanotide) is a synthetic cyclic heptapeptide derived from Melanotan II. FDA-approved in 2019 as Vyleesi, it acts on MC3R and MC4R receptors in the central nervous system, distinguishing it from peripheral vasodilator-based compounds.
What the Research Shows
Research has examined PT-141’s mechanism through central melanocortin pathways rather than vascular effects. Studies investigate its effects on dopaminergic and oxytocinergic systems.
FDA approval provides extensive clinical trial data on safety, pharmacokinetics, and efficacy. This makes PT-141 one of the best-characterised peptides for melanocortin receptor research.
Why Australian Researchers Choose Purpose Labs
Every batch is tested at a leading Australian university — HPLC and mass spectrometry confirm ≥99% purity. No generic overseas certificates.
→ Explore the Peptide Research Library
Purity: ≥99% (HPLC)
Form: Lyophilised powder
Molecular Weight: 1025.2 Da
CAS: 189691-06-3
Structure: Cyclic heptapeptide
Research: PubMed
▸ Australian university verified
▸ ≥99% purity guaranteed
▸ Same-day dispatch from Sydney
▸ Research-grade lyophilised powder
Related Research and Resources
For research use only. Not for human consumption.




